A report says an Eli Lilly drug helped protect muscle mass when combined with Novo's Wegovy, addressing a common worry about lean mass loss.
Recap by typeshit. Full story at emy.
Researchers are starting to explain the shifts in libido some GLP-1 users report. The full story covers what scientists have found so far.
Bikman says the added glucagon receptor push raises energy use and liver fat burning, and points to 24.2% weight loss on 12 mg in phase 2.
9:08
Archibald takes on a common question about low retatrutide doses and the drug's glucagon action. His view, not settled science, and retatrutide is still unapproved.
He says close to 40% of weight lost in the trial's body-scan group was lean mass, and argues muscle loss isn't the drug's fault.
Retatrutide is still in clinical trials, yet people are discussing using it online. A new analysis takes a first systematic look at the side effects they describe.
European Business Magazine says oral Wegovy has 1.5 million patients and about $843m in first-half sales, while semaglutide generics spread in India and Canada.
Loading…